Marksans Pharma Limited has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical wholesale and distribution company. The acquisition represents a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.

Acquisition Details

  • Target Entity: ABCnow GmbH, a foreign company registered in Germany
  • Business Description: Pharmaceutical wholesale and distribution company headquartered in Flensburg, Germany, primarily engaged in marketing & distribution of OTC products in Germany
  • Financial Performance: Turnover of €227,233.69 as of December 31, 2025; achieved revenue of €510,215.60 in 2024
  • Incorporation Date: 2023

Transaction Structure

  • Percentage Acquired: 100% share capital of ABCnow GmbH
  • Consideration Type: Cash consideration
  • Acquisition Cost: Total consideration of €892,384
  • Expected Completion: By 31 July 2026

Regulatory and Compliance Aspects

  • Related Party Status: Transaction does not fall within related party transactions; promoters/promoter group have no interest in ABCnow GmbH
  • Governmental Approvals: No regulatory approvals required for the acquisition
  • SEBI Disclosure: Made under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Strategic Rationale

The acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. ABCnow presents an attractive opportunity to gain access to German pharma markets, and with its capable and well-trained team of professionals, can support Marksans' growth aspirations. With this acquisition, Marksans will create its own front end in Germany to market its products.

Financial Impact

The financial impact of the acquisition is quantified at €892,384 cash outflow for 100% ownership. The target company reported turnover of €227,233.69 in 2025 and €510,215.60 in 2024.